Table 2.

Antimicrobial, cytotoxicity, and hemolytic activities of the three most active derivatives synthesized in this study ^a.

Compound	C. difficile ATCC 700057	C. difficile 132 b (RT027)	S. aureus ATCC 29213	S. aureus ATCC 43300 c	S. aureus NCTC 104422 c,d	E. faecalis ATCC 29212	S. pneumoniae ATCC 49619	E. coli ATCC 25922	CC50 e	HC50 f
40	8	8	16	8	16	32	16	64	32	32
41	16	16	8	4	8	8	16	128	16	32
42	8	8	8	8	8	8	8	32	32	32
1 [30]	8 g	8 h	2	-	-	2	2	16	-	-
2 [31]	-	32	4	2	4	4	4	8	27.4	94% i
3 [19]	8 g	8 h	2	-	2	4	8	>128	-	-
4 [31]	-	8	8	4	4	8	4	8	14.2	23% i
vanc	0.5	0.5	1	-	1	4	1	>16	-	-

^a Values are reported as MIC values in μg/mL. ^b C. difficile PCR Ribotype (RT027). ^c Methicillin resistant S. aureus (MRSA). ^d Testing performed by the Community for Open Antimicrobial Drug Discovery (CO-ADD). ^e Cytotoxicity; determined on HEK293 cells. ^f Hemolysis; determined by lysis of sheep erythrocytes ^g C. difficile strain tested M7404 (RT027). ^h C. difficile strain tested R20291 (RT207). ⁱ % hemolysis at 50 µg/mL. vanc = vancomycin. Coloured cells refer to the same activities.